LOS ANGELES, July 18 (Xinhua) — The U.S. Food and Drug Administration (FDA) on Monday approved a new drug to prevent infants and toddlers from: RSV, or the virus that causes respiratory disease
The drug, called Beyfortus, is a monoclonal antibody that is active against RSV. It is approved for use in newborns. and infants born during or during the first RSV season. and in children up to 24 months of age who remained at risk for severe RSV during the second RSV season.
John Farley, director of the Bureau of Infectious Diseases at the Drug Evaluation and Research Center of the Office It said the RSV virus can cause serious disease in some infants and children. and leads to many hospitalizations in emergency rooms and hospitals each year.
Farley added that the approval meets the demand for products. that will reduce the impact of RSV on children, families and the health care system.
RSV is a virus that causes acute respiratory tract infections in people of all age groups. While most infants and young children have mild flu-like symptoms, However, some babies may suffer from lower respiratory tract diseases such as pneumonia and bronchiolitis. especially when infected for the first time
American Academy of Pediatrics revealed that children under 12 months in the United States Admitted to hospital due to RSV virus Approximately 1-3 percent each year.
(Xinhua file photo: Students at an elementary school in Chicago, US, March 14, 2022.)
related tags
2023-07-18 10:59:24
#approves #drug #prevent #RSV #virus #infants #children
